Flexport’s Customs Technology Suite is part of its Fall 2025 Technology Release, which includes 25+ new technology and AI products that help customers mitigate supply chain volatility. Flexport, the ...
Fed-batch and batch bioprocessing still dominate monoclonal antibody (mAb) production, but that must change if mAbs are to become economically viable therapeutic options. Current production techniques ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback